Xenetic Biosciences Profit Margin

Xenetic Biosciences (XBIO) currently reports a profit margin of -75.91% as of June 2026. That compares with -126.03% in the prior-year period — up 39.8% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Xenetic Biosciences's profit margin history and peer comparisons.

Xenetic Biosciences's profit margin increased from -126.03% to -75.91% — a 39.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Xenetic Biosciences's profit margin of -75.91% is lower than the Healthcare sector average of 15.29%. That is roughly 596.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Xenetic Biosciences's current -75.91% should be judged against Healthcare norms (sector average: 15.29%) and against XBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -75.91%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Xenetic Biosciences, and consider following XBIO for alerts when major investors trade the stock.